Today, we reported our first quarter 2026 financial results alongside continued business progress across our portfolio of oral small molecule GPCR-targeted programs. Read the full announcement: https://lnkd.in/gN7wR8Fx #GPCR #Biotech #DrugDiscovery #PatientsInspireOurUrgency
Septerna
Biotechnology
South San Francisco, California 16,044 followers
Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.
About us
Septerna is on a mission to make the promise of future GPCR medicines a reality for patients. Combining the latest advances in biochemical, structural and computational drug discovery approaches, we have built an industrialized platform to precisely control and modulate GPCR biology and pharmacology to discover and develop new high-impact medicines. With our Native Complex Platform™, we are opening a new frontier in GPCR small molecule discovery technologies to expand the druggable GPCR landscape. We are always looking for talented scientists, drug hunters, and business professionals to join our mission to launch a new era of GPCR medicines. If you’re passionate about innovation, energized by teamwork, and fueled by the desire to change patient lives, join us and become a part of the Septerna story!
- Website
-
http://www.septerna.com
External link for Septerna
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
Locations
-
Primary
Get directions
250 E Grand Ave
65
South San Francisco, California 94080, US
Employees at Septerna
Updates
-
We’re looking forward to participating in the Bank of America Securities Health Care Conference next week in Las Vegas. Join our CEO and Co-founder Jeff Finer, M.D., Ph.D., as he shares Septerna’s progress advancing oral GPCR therapeutics across our programs. 📅 Tuesday, May 12 at 5:00 p.m. PT A live webcast will be available in the investors section of our website and archived for 30 days following the presentation. https://lnkd.in/gxFzWDJQ #Biotech #GPCRs #DrugDiscovery #BofASecurities
-
Recently, 90+ #TeamSepterna members traded the lab and office for the shoreline. We partnered with the Surfrider Foundation - San Mateo County for our first outdoor community service event in honor of Earth Day. The day was a meaningful way to come together as a team to honor a beloved colleague whose love of the outdoors continues to inspire us. In just a few hours at Pillar Point Harbor, our team: ✅ Collected 180 lbs of trash ✅ Recovered 15 lbs of recyclables ✅ Pulled 345 cigarette butts from the sand and parking lots ✅ Rescued three crabs from the debris and uncovered some unexpected finds along the way (including a plastic trash can, surfboard pieces, and even a car tire!) The same care and dedication that drive our team to advance new medicines for patients also call us to show up for the places and people around us. Days like this one remind us why community matters. Huge thanks to The Surfrider Foundation for the partnership and the vital work you do to protect our oceans, waves, and beaches every day. #EarthDay #CommunityEngagement #Biotech
-
We’re thrilled to announce the dosing of the first participants in our Phase 1 clinical trial of SEP-479, a potent oral small molecule PTH1R agonist being developed for the treatment of hypoparathyroidism. Hypoparathyroidism is a lifelong condition that many patients must manage with either high doses of calcium supplements several times a day or daily parathyroid hormone (PTH) injections, both of which can place a substantial burden on patients over time. SEP-479 is designed to directly target the PTH receptor with the potential to be a differentiated once-daily oral therapy that provides patients full-day calcium control. Read the full announcement: https://lnkd.in/eb96E3tM #Hypoparathyroidism #PTH1R #GPCR #ClinicalTrials #RareDisease
-
Thank you to everyone who joined us at the American Academy of Allergy, Asthma & Immunology - AAAAI Annual Meeting 2026 in Philadelphia, where we shared Phase 1 data from our clinical trial of SEP-631 in mast cell-driven diseases. It was a privilege to connect with colleagues in the allergy and immunology community who share our commitment to advancing new therapies for patients with mast cell-driven diseases. Their unmet needs drive our urgency, and we’re grateful for the opportunity to share this important milestone on the path toward potential new treatment options. ICYMI, the webcast replay is now available on our investor relations page: https://ir.septerna.com/ #AAAAI2026 #MRGPRX2 #ChronicUrticaria #GPCR #Biotech
-
-
Today, we are presenting data from our first-in-human Phase 1 study of SEP-631 at the American Academy of Allergy, Asthma & Immunology - AAAAI, Asthma and Immunology (#AAAAI) Annual Meeting 2026. This proof-of-mechanism study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-631, including an icatibant skin challenge to assess target engagement in healthy volunteers. These results further support the potential of selective oral MRGPRX2 inhibition as a differentiated treatment approach for patients with CSU and other mast cell-driven diseases. Read the full press release here: https://lnkd.in/gfphataK Join us for an investor webcast tomorrow, March 2, at 8:00 a.m ET to discuss the Phase 1 results and Phase 2 development strategy for SEP-631.
-
Today, #TeamSepterna is wearing purple in honor of #RareDiseaseDay. For the approximately 70,000 people in the U.S. living with hypoparathyroidism — a condition where low parathyroid hormone levels lead to debilitating symptoms like muscle cramps, tingling, and brain fog — treatment options remain limited. We're working to change that by developing an oral small molecule therapy targeting PTH1R to help normalize calcium levels and improve patients’ daily lives. Rare diseases deserve urgent attention, and the patients and caregivers who navigate these conditions inspire the work we do. #PatientsInspireOurUrgency #Hypoparathyroidism #GPCR #Biotech #DrugDiscovery
-
Join us at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd at 3:10 PM ET in Boston. Our CEO and Co-founder, Jeff Finer, M.D., Ph.D., will discuss the progress we are making towards unlocking the therapeutic potential of GPCRs through our innovative pipeline targeting endocrinology, immunology, and metabolic diseases. Can’t make it to Boston? Watch the webcast on our investor page: https://ir.septerna.com/ https://lnkd.in/g6fidMC5 #BiotechInnovation #GPCRs #TDCowenHealthcare
-
Our hearts are with Kate Morse’s family and with all those affected by this week’s Tahoe avalanche tragedy. We are grateful for the mark Kate left on Septerna. Her impact on our team and mission will not be forgotten.
With heavy hearts, we at Septerna honor and remember Kate Morse, a bright light and unforgettable force of energy who we tragically lost in the Tahoe avalanche earlier this week. Kate led our Commercial Strategy and New Product Planning function and contributed significantly to the entire organization through her strength as an inspiring leader and her dedication to the patient communities we serve. Kate was a devoted wife and mother who proudly brought her children to the office, serving as a truly caring and powerful example to our teams. Kate had an immense impact on her friends and colleagues and was an integral member of Septerna’s leadership team, driving key initiatives forward with passion. One example was Kate championing building relationships with patient advocacy groups to help expose the broader Septerna team firsthand to the voices of patients we all hope to serve. Kate’s absence has been deeply felt these past few days as we attempt to grapple with the unimaginable reality of losing her. We will continue to miss her presence, and our hearts will keep Kate’s memory and family close in the time ahead.
-
-
#TeamSepterna wishes a happy Lunar New Year to all who are celebrating! May the Year of the Horse bring good fortune and success in the year ahead. #LunarNewYear #YearOfTheHorse